RecruitingPhase 4NCT05139238

Postpartum Hypertension Study

Oral Nifedipine Versus Intravenous Labetalol for Postpartum (PP) Hypertensive Emergency: A Randomized Clinical Trial (RCT)

Sponsor

Columbia University

Enrollment

104 participants

Start Date

Jul 4, 2022

Study Type

INTERVENTIONAL

Conditions

Postpartum Pregnancy-Induced Hypertension Postpartum Preeclampsia Pregnancy-Induced Hypertension in Postpartum Hypertensive Emergency

Summary

The purpose of this study is to assess which blood pressure medication (intravenous labetalol or oral nifedipine) works better in treating severely elevated blood pressure in women who have just delivered a baby.

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria3

Patients admitted to labor and delivery (L\&D) with blood pressure (BP) in severe range, defined as a systolic ≥160 mm Hg and/or diastolic ≥110 mm Hg
Postpartum, immediately to 6 weeks postpartum
With a prior diagnosis of chronic hypertension (not on medication) or hypertensive disorder of pregnancy

Exclusion Criteria2

They may not have previously had exposure to either study medication within the previous 24-hour period.
Patients with a known atrial-ventricular heart block or moderate to severe bronchial asthma will be excluded, or other contraindication to receiving either study medication